We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) announced that the FDA has approved its CD19-directed chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel).
The therapy is approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B.
This new promising immunotherapy involves using a patient’s own immune cells to attack cancer cells. The candidate was added to the company’s portfolio with the acquisition of Celgene Corporation.
The FDA approval of Breyanzi was based on data from the TRANSCEND NHL 001 (017001) study, in which 268 patients with R/R LBCL received Breyanzi. In the study, the therapy demonstrated a 73% overall response rate and a 54% complete response (CR) rate. Breyanzi demonstrated sustained responses in patients who achieved a CR with a median duration of response not reached.
It has been granted the Priority Medicines (PRIME) designation for R/R DLBCL in the European Union and a Marketing Authorization Application (MAA) is currently under review with the European Medicines Agency.
While this innovative space promises potential, competition is stiff from the likes of Novartis’ (NVS - Free Report) Kymriah and Gilead’s (GILD - Free Report) Yescarta.
Meanwhile, approval of new drugs will add a new stream of revenues for Bristol Myers, which should propel growth in the coming quarters.
The company’s shares have lost 9.2% in the past year against the industry's growth of 14.1%.
It recently reported better-than-expected results for the fourth quarter of 2020, as multiple myeloma (MM) drug, Revlimid, and blood thinner drug, Eliquis, drove growth for the company. Another MM drug, Pomalyst, also drove the upside. Opdivo too returned to growth after declining in the third quarter amid stiff competition from Merck’s (MRK - Free Report) Keytruda.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy
Bristol Myers Squibb (BMY - Free Report) announced that the FDA has approved its CD19-directed chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel).
The therapy is approved for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B.
This new promising immunotherapy involves using a patient’s own immune cells to attack cancer cells. The candidate was added to the company’s portfolio with the acquisition of Celgene Corporation.
The FDA approval of Breyanzi was based on data from the TRANSCEND NHL 001 (017001) study, in which 268 patients with R/R LBCL received Breyanzi. In the study, the therapy demonstrated a 73% overall response rate and a 54% complete response (CR) rate. Breyanzi demonstrated sustained responses in patients who achieved a CR with a median duration of response not reached.
It has been granted the Priority Medicines (PRIME) designation for R/R DLBCL in the European Union and a Marketing Authorization Application (MAA) is currently under review with the European Medicines Agency.
While this innovative space promises potential, competition is stiff from the likes of Novartis’ (NVS - Free Report) Kymriah and Gilead’s (GILD - Free Report) Yescarta.
Meanwhile, approval of new drugs will add a new stream of revenues for Bristol Myers, which should propel growth in the coming quarters.
The company’s shares have lost 9.2% in the past year against the industry's growth of 14.1%.
It recently reported better-than-expected results for the fourth quarter of 2020, as multiple myeloma (MM) drug, Revlimid, and blood thinner drug, Eliquis, drove growth for the company. Another MM drug, Pomalyst, also drove the upside. Opdivo too returned to growth after declining in the third quarter amid stiff competition from Merck’s (MRK - Free Report) Keytruda.
Bristol-Myers currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>